Efficacy of Reslizumab in Older Patients (≥65 years) with Asthma and Elevated Blood Eosinophils: Results from a Pooled Analysis of Two Phase 3, Placebo-Controlled Trials

Rationale Reslizumab was recently shown to improve multiple measures of asthma control in patients aged 12-75 years with inadequately controlled asthma and blood eosinophils >=400cells/μL (Castro et al., Lancet Resp Med. 2015).

Bibliographic Details

Published in:	Journal of allergy and clinical immunology 2016-02, Vol.137 (2), p.AB86-AB86
Main Authors:	Bernstein, David I., MD, FAAAAI, Mansfield, Lyndon, Zangrilli, James, Garin, Margaret
Format:	Article
Language:	English
Subjects:	Allergy and Immunology
Citations:	Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!